Natera, Inc. (NASDAQ:NTRA) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Natera (NTRA) Launches Zenith Genomic Assay On March 12, 2026, Natera, Inc. (NASDAQ:NTRA) announced the commercial launch of Zenith, a whole-genome sequencing assay engineered to significantly improve the diagnosis of rare genetic conditions. Zenith, with its genomic analysis, aims to shorten the diagnostic odyssey for the 30 million Americans affected by rare diseases. In its announcement, the ...

Core Insights - Natera, Inc. (NTRA) is a diagnostic company specializing in molecular testing services, with a focus on oncology, women's health, and organ health [1] - The oncology segment, particularly minimal residual disease monitoring (MRD), is the strongest area for the company [1] - In 2025, Natera plans to implement new product launches, secure new Medicare coverages, and advance its offerings [1]

Core Insights - Natera (NTRA) has launched Zenith genomics, a next-generation whole genome sequencing assay aimed at enhancing the detection and diagnosis of rare genetic diseases [2][8] - The technology was developed in partnership with MyOme, which specializes in clinical whole genome analysis [2][4] - Natera plans to utilize its extensive infrastructure, including electronic medical record integration and clinical support systems, to distribute Zenith genomics across the United States [3][6] Company Developments - The launch of Zenith genomics is expected to strengthen Natera's growth outlook by expanding its footprint in the rare disease diagnostics market, which is rapidly growing [6] - The assay aims to improve diagnostic clarity and accuracy for patients with suspected rare genetic disorders by utilizing advanced sequencing technologies [10][11] - Natera's current market capitalization stands at $26.62 billion [7] Market Context - Rare diseases affect approximately 30 million people in the United States, with many patients experiencing significant delays in diagnosis [13] - The economic burden of rare diseases in the U.S. was estimated at $997 billion in 2019, underscoring the need for improved diagnostic solutions [13] - The genetic testing market is projected to reach $27.32 billion by 2026, with a compound annual growth rate (CAGR) of 11.3% through 2035, driven by increasing incidences of genetic disorders and advancements in testing technologies [14]

Core Insights - Natera has experienced remarkable growth in its Signatera product over the past few years, with over 100 publications supporting its clinical evidence [1] - The company has acquired technology for PhasED variance, which enhances sensitivity in its diagnostics [1] - Natera's women's health business is performing well, holding over 40% market share in non-invasive prenatal testing (NIPT) [1] - Despite increasing competition, Natera is proactively addressing challenges in the market [1]

Summary of Natera Conference Call Company Overview - **Company**: Natera (NasdaqGS:NTRA) - **Industry**: Life Sciences Tools and Diagnostics Key Points Signatera Growth and Performance - **Volume Growth**: Signatera has shown significant growth, with 22,500 growth units last quarter and a total of 225,000 units overall in the quarter, indicating a strong upward trajectory in demand [4][6] - **Sequential Volume Growth**: The average sequential volume growth is suggested to be assessed over the trailing four quarters to normalize for seasonality and variability [4][5] - **ASP (Average Selling Price)**: The ASP for Signatera is approximately $1,225 as of Q4, with reimbursement rates from Medicare being higher than commercial payers [7][8][10] Reimbursement Landscape - **Medicare Coverage**: Medicare broadly reimburses Signatera across various tumor types, which is crucial for its market penetration [12][14] - **Commercial Payers**: There is a significant opportunity to increase reimbursement rates from commercial payers, particularly Medicare Advantage plans, where reimbursement rates are currently around 80% [102][104] Clinical Evidence and Trials - **Ongoing Studies**: Natera is focused on generating clinical evidence through ongoing studies and presentations at academic conferences, which are not binary events but rather a continuous stream of data [30][31][38] - **Foresight Acquisition**: The acquisition of Foresight is aimed at enhancing the analytical performance of Signatera, particularly in sensitivity and clinical evidence [39][55] FDA Approval and Market Positioning - **FDA-Approved Version**: An FDA-approved version of Signatera is expected this year, which could enhance physician confidence and demand for the test [57][63] - **Standard of Care**: There is a growing belief among physicians that Signatera will become part of the standard of care in cancer monitoring, similar to routine CT scans [65][66] R&D Investment - **R&D Spending**: Natera has guided an $800 million R&D spend for the year, a 30% increase year-over-year, primarily focused on Signatera and colorectal cancer early detection screening [69][72] - **Clinical Trials**: Significant investments are being made in clinical trials to support existing franchises and new product development [70][72] Women's Health Business - **Fetal Focus Product**: The Fetal Focus product is positioned as complementary to existing offerings, with no significant cannibalization expected between it and Horizon volumes [84][89] - **Panorama NIPT**: The Panorama NIPT assay continues to see improvements in reimbursement rates and is becoming a standard of care [99][101] Colorectal Cancer Screening - **Market Opportunity**: There is a substantial market for early cancer detection in colorectal cancer, with around 40 million people not currently receiving adequate screening [122][130] - **Technological Challenges**: Launching new products in this space requires significant investment and infrastructure, which Natera is well-positioned to handle [134][135] Future Outlook - **Growth Drivers**: The company anticipates that the combination of Signatera's growth, new product launches, and advancements in colorectal cancer screening will drive significant shareholder value in the coming years [138][139] This summary encapsulates the key insights from the Natera conference call, highlighting the company's growth trajectory, market positioning, and strategic initiatives in the life sciences diagnostics industry.

Core Insights - Natera has recently announced its Q4 results, which were well received and set expectations for 2026 [1] - The company experienced significant revenue growth in the quarter, with record volumes for Signatera and strong gross margins [2] Financial Performance - In Q4, Natera achieved a gross margin of approximately 67%, which adjusted for true-ups, was close to 64% [2] - The company reported record absolute volumes and growth units for Signatera, indicating robust demand and operational performance [2]

Summary of Natera's Conference Call Company Overview - Natera is a diagnostics and life science tools company, focusing on genetic testing and monitoring, particularly in oncology and women's health [1] Financial Performance - Q4 results showed strong revenue growth, with record volumes for Signatera, a product for minimal residual disease (MRD) monitoring [2][3] - Gross margins reached approximately 67%, with a sequential increase of 240 basis points from Q3 [3] - The company generated over $100 million in free cash flow for the year, indicating strong financial health [9] - Natera aims for continued revenue growth across its portfolio, particularly in women's health and organ health, with a focus on pricing improvements for Signatera [11] Product Development and Market Strategy - Natera is expanding Signatera's penetration among oncologists, with 50% of oncologists currently ordering the test [14] - The company sees significant opportunities for growth in both indication expansion and deeper adoption within existing practices [15][16] - Natera is committed to aggressive R&D spending to support clinical trials and new product development, maintaining a stable SG&A year-on-year [12] Coverage and Reimbursement - Approximately 30%-35% of Signatera's volume comes from non-covered areas, representing a potential $200 million opportunity if coverage expands [20] - Natera is actively working with Medicare to improve coverage for various cancer types, with expectations for more announcements in the near future [24][25] - The company has improved its reimbursement rates from Medicare Advantage plans, currently at 80% compared to 99% for Medicare fee-for-service [27] Clinical Guidelines and Adoption - Clinical guidelines remain crucial for the adoption of Signatera, with ongoing studies expected to support guideline inclusion for colorectal cancer and muscle-invasive bladder cancer [30][31] - Natera is optimistic about the potential for guideline updates that could enhance the adoption of Signatera in clinical practice [32][33] Women's Health Segment - Natera's women's health business is projected to grow mid-single digits, driven by increased interest in carrier screening and ongoing product innovation [53][54] - The recent launch of the Fetal Focus test is part of Natera's strategy to maintain competitiveness in a challenging market [56] R&D and Future Outlook - Natera is focused on growing its R&D investments to drive innovation and improve product offerings, with a bias towards ambitious clinical trials [71] - The company aims to achieve sustainable earnings per share through revenue growth and efficient operational management [66] Conclusion - Natera is well-positioned for future growth with a strong product pipeline, ongoing improvements in reimbursement, and a commitment to innovation in both oncology and women's health [73]

Core Insights - Natera had a strong performance in Q4 2025, exceeding internal expectations in both volumes and revenues [3] - The company reported a significant increase in gross margins, with organic gross margins reaching approximately 64% and 67% when including true-ups [3] - The growth across the portfolio was robust, with the Signatera product achieving record unit sales and notable clinical trial data contributing to its success [4] Financial Performance - Q4 2025 finished with strong revenue growth, surpassing consensus estimates [2] - Gross margin improved by approximately 240 basis points, indicating strong operational efficiency [3] - The overall performance in 2025 was characterized by significant growth across various product lines [4] Strategic Focus - Key priorities for 2026 include maintaining growth momentum and leveraging positive clinical trial outcomes to drive further product adoption [2][4] - Continued emphasis on enhancing gross margins and operational performance is expected to be a focus area moving forward [3]

Core Insights - The fourth quarter of 2025 saw mixed results for midcap stocks, with the Russell Midcap® Growth Index decreasing by 3.70% and the Russell Midcap® Value Index increasing by 1.41% [1] - The Russell Midcap Growth Index rose by 8.66% in 2025, trailing the Russell Midcap Value Index's 11.04% return [1] - Carillon Eagle Mid Cap Growth Fund anticipates favorable equity market conditions and identifies potential opportunities in sectors such as Cyclicals, Healthcare, Information Technology, Financials, and Consumer Spending through 2026 [1] Company Insights: Natera, Inc. (NASDAQ:NTRA) - Natera, Inc. is highlighted as a leading contributor to the Carillon Eagle Mid Cap Growth Fund, specializing in ctDNA molecular testing services [2][3] - As of March 03, 2026, Natera's stock closed at $207.04 per share, with a one-month return of 0.70% and a 52-week gain of 39.97% [2] - Natera reported revenue of approximately $666 million in Q4 2025, representing a growth of around 40% compared to Q4 2024 [4] - The company’s flagship Signatera oncology test has driven growth, with volumes exceeding consensus estimates, leading to an increase in revenue growth guidance [3] - Natera's market capitalization stands at $28.872 billion, and it has shown strengthening profitability with rising gross margins and sustained positive free cash flow [2][3]

Core Insights - Natera, Inc. will present new data in genitourinary malignancies at the ASCO GU symposium scheduled for February 26-28, 2026 [1] - The data will include four oral presentations focused on muscle-invasive bladder cancer (MIBC) [1] - The findings reinforce the role of Signatera in identifying patients who benefit from adjuvant immunotherapy [1]